Search

Your search keyword '"Aram, Jalal"' showing total 45 results
Start Over Author "Aram, Jalal"
45 results on '"Aram, Jalal"'

1. Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.

Author

Locke, Jeffrey, Pillar, Chris, Castanheira, Mariana, Carvalhaes, Cecilia, Andes, David, Aram, Jalal, Andrzejewski, Christina, Bartizal, Ken, Das, Anita, Sandison, Taylor, Thompson, George, and Pappas, Peter

Subjects
Candida species, antifungal therapy, candidemia, echinocandin, invasive candidiasis, Caspofungin, Echinocandins, Humans, Antifungal Agents, Candidemia, Candidiasis, Invasive, Microbial Sensitivity Tests, Male, Female, Middle Aged, Candida, Adult, Aged, Lipopeptides, Candida albicans, Treatment Outcome, Candida tropicalis, Candida glabrata
Abstract

Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida species using the Clinical and Laboratory Standards Institute reference broth microdilution method. There were 93 patients in the modified intent-to-treat population who received rezafungin; 94 received caspofungin. Baseline Candida species distribution was similar in the two treatment groups; C. albicans (occurring in 41.9% and 42.6% of patients in the rezafungin and caspofungin groups, respectively), C. glabrata (25.8% and 26.6%), and C. tropicalis (21.5% and 18.1%) were the most common pathogens. Rates of global cure and mycological eradication at day 14 and day 30 all-cause mortality by Candida species were comparable in the rezafungin and caspofungin treatment groups and did not appear to be impacted by minimal inhibitory concentration (MIC) values for either rezafungin or caspofungin. Two patients had baseline isolates with non-susceptible MIC values (both in the rezafungin group: one non-susceptible to rezafungin and one to caspofungin, classified as intermediate); both were candidemia-only patients in whom rezafungin treatment was successful based on the day 30 all-cause mortality endpoint. This analysis of ReSTORE demonstrated the efficacy of rezafungin for candidemia and IC in patients infected with a variety of Candida species.

Published
2024

3. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials

Author

Thompson, George R, III, Soriano, Alex, Honore, Patrick M, Bassetti, Matteo, Cornely, Oliver A, Kollef, Marin, Kullberg, Bart Jan, Pullman, John, Hites, Maya, Fortún, Jesús, Horcajada, Juan P, Kotanidou, Anastasia, Das, Anita F, Sandison, Taylor, Aram, Jalal A, Vazquez, Jose A, and Pappas, Peter G

Published
2024
Full Text
View/download PDF

7. Stress and anxiety among physicians during the COVID-19 outbreak in the Iraqi Kurdistan Region: An online survey.

Author

Banaz A Saeed, Nazar P Shabila, and Aram Jalal Aziz

Subjects
Medicine, Science
Abstract

BackgroundDuring infectious disease outbreaks, healthcare workers are at high risk of infection, infecting others, and psychological distress. This study aimed to determine the prevalence of stress and anxiety in physicians during the COVID-19 outbreak in the Iraqi Kurdistan Region and assess their associated factors.MethodsThis cross-sectional study was carried out in Erbil, Iraqi Kurdistan Region, from March 28 to April 15, 2020. An online self-administered survey questionnaire was used to collect data from physicians working in specialized COVID-19 centers and other healthcare facilities. The level of stress was measured based on the 10-items Perceived Stress Scale. The level of anxiety was measured based on the 7-item Generalized Anxiety Disorder scale.ResultsA total of 370 participants responded to the perceived stress component of the survey, of whom 57 (15.4%) had low perceived stress, 249 (67.3%) had moderate stress, and 64 (17.3%) had high stress. Being female was significantly associated with having moderate/high stress (adjusted odds ratio (AOR) = 2.40 (95% CI 1.31-4.39)). A total of 201 participants responded to the generalized anxiety disorder component of the survey, of whom 19 (9.5%) had no anxiety, 57 (28.4%) had mild anxiety, 79 (39.3%) had moderate anxiety, and 46 (22.9%) had severe anxiety. Working in COVID-19 centers (AOR = 2.23 (95% CI 1.02-4.86)) and being general practitioners (AOR = 4.16 (95% CI 1.14-15.14)) were significantly associated with having moderate/severe anxiety.ConclusionA considerable proportion of physicians experience stress and anxiety during the COVID-19 outbreak in Iraqi Kurdistan region. Generalists and those in special COVID-19 units report the greatest anxiety. There a need to establish mechanisms to reduce the risks of stress and anxiety among physicians. Mental health coping interventions through counseling should be based on COVID-19 protocol guidelines. Interventions should also emphasize physicians' ability to work safely and efficiently in providing care to the patients.

Published
2021
Full Text
View/download PDF

20. In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China

Author

Jing,Ran, Morrissey,Ian, Xiao,Meng, Sun,Tian-Shu, Zhang,Ge, Kang,Wei, Guo,Da-Wen, Aram,Jalal A, Wang,Jeffrey, Utt,Eric A, Wang,Yao, Xu,Ying-Chun, Jing,Ran, Morrissey,Ian, Xiao,Meng, Sun,Tian-Shu, Zhang,Ge, Kang,Wei, Guo,Da-Wen, Aram,Jalal A, Wang,Jeffrey, Utt,Eric A, Wang,Yao, and Xu,Ying-Chun

Abstract

Ran Jing,1– 3 Ian Morrissey,4 Meng Xiao,1,3 Tian-Shu Sun,3,5 Ge Zhang,1,3 Wei Kang,1,3 Da-Wen Guo,6 Jalal A Aram,7 Jeffrey Wang,8 Eric A Utt,7 Yao Wang,1,3 Ying-Chun Xu1– 3 1Department of Laboratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Graduate School, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 3Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Beijing, People’s Republic of China; 4IHMA Europe Sarl, Monthey, Valias, Switzerland; 5Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 6Department of Laboratory Medicine, the First Clinical Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, People’s Republic of China; 7Medical Affairs, Pfizer Inc, Groton, CT, USA; 8Clinical Development, Pfizer, Beijing, People’s Republic of ChinaCorrespondence: Ying-Chun Xu; Yao Wang, Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Number 1, Shuaifuyuan Road, Dongcheng District, Beijing, People’s Republic of China, Fax +86 10 69159766, Email xycpumch@139.com; yaoo_wang@163.comPurpose: Monitoring antifungal susceptibility patterns for new or established antifungals is imperative. Antifungal resistance is frequent in molds, frequently leading to invasive mold infections (IMIs) in immunocompromised patients with high morbidity and mortality. Limited availability of effective antifungals for treatment of IMIs in China is an enormous challenge. The purpose of this study was to monitor in vitro antifungal resistance profiles of mold i

Published
2022

25. Stress and anxiety among physicians during the COVID-19 outbreak in the Iraqi Kurdistan Region: An online survey

Author

Nazar P. Shabila, Aram Jalal Aziz, and Banaz Adnan Saeed

Subjects
Male, Coping (psychology), Viral Diseases, Cross-sectional study, Health Care Providers, Emotions, Psychological intervention, Perceived Stress Scale, Social Sciences, Anxiety, Surveys, Severity of Illness Index, 0302 clinical medicine, Medical Conditions, Surveys and Questionnaires, Medicine and Health Sciences, Odds Ratio, Psychology, 030212 general & internal medicine, Medical Personnel, Multidisciplinary, Anxiety Disorders, Professions, Infectious Diseases, Research Design, Iraq, Medicine, Female, medicine.symptom, Research Article, Adult, medicine.medical_specialty, Generalized anxiety disorder, Science, Psychological Stress, Neuropsychiatric Disorders, Neuroses, Research and Analysis Methods, 03 medical and health sciences, Sex Factors, General Practitioners, Physicians, Mental Health and Psychiatry, medicine, Humans, Internet, Survey Research, business.industry, SARS-CoV-2, Biology and Life Sciences, COVID-19, Covid 19, Odds ratio, medicine.disease, Mental health, 030227 psychiatry, Health Care, Cross-Sectional Studies, Family medicine, People and Places, Population Groupings, business, Stress, Psychological
Abstract

Background During infectious disease outbreaks, healthcare workers are at high risk of infection, infecting others, and psychological distress. This study aimed to determine the prevalence of stress and anxiety in physicians during the COVID-19 outbreak in the Iraqi Kurdistan Region and assess their associated factors. Methods This cross-sectional study was carried out in Erbil, Iraqi Kurdistan Region, from March 28 to April 15, 2020. An online self-administered survey questionnaire was used to collect data from physicians working in specialized COVID-19 centers and other healthcare facilities. The level of stress was measured based on the 10-items Perceived Stress Scale. The level of anxiety was measured based on the 7-item Generalized Anxiety Disorder scale. Results A total of 370 participants responded to the perceived stress component of the survey, of whom 57 (15.4%) had low perceived stress, 249 (67.3%) had moderate stress, and 64 (17.3%) had high stress. Being female was significantly associated with having moderate/high stress (adjusted odds ratio (AOR) = 2.40 (95% CI 1.31–4.39)). A total of 201 participants responded to the generalized anxiety disorder component of the survey, of whom 19 (9.5%) had no anxiety, 57 (28.4%) had mild anxiety, 79 (39.3%) had moderate anxiety, and 46 (22.9%) had severe anxiety. Working in COVID-19 centers (AOR = 2.23 (95% CI 1.02–4.86)) and being general practitioners (AOR = 4.16 (95% CI 1.14–15.14)) were significantly associated with having moderate/severe anxiety. Conclusion A considerable proportion of physicians experience stress and anxiety during the COVID-19 outbreak in Iraqi Kurdistan region. Generalists and those in special COVID-19 units report the greatest anxiety. There a need to establish mechanisms to reduce the risks of stress and anxiety among physicians. Mental health coping interventions through counseling should be based on COVID-19 protocol guidelines. Interventions should also emphasize physicians’ ability to work safely and efficiently in providing care to the patients.

Published
2021

30. The applier of general rules to individual case and Its impact on building community peace

Author

Aram Jalal Abdullah

Abstract

What prompted me to participate in your esteemed conference is: - Theme: Ideologies and Genocide: The Religious Factor - Which is first: shedding light on a delicate and a sensitive topic, namely: Who fulfills applying general rules to individual case and what impact it has on societal peace, to know the causes of the emergence of extremist ideas and ways to treat them, because what Humankind in general, and countries with different religions, sects, and minorities in particular, is experiencing from dispersal, scattering and spilling the blood of its components. It is only one of the causes of erroneous diligence in understanding the religious text and error in the mechanism of application of texts in issues over which there are various sects and intellectual trends. And its development, made life in renewal and expansion, and calamities abounded and a renewed vision of the facts, and these issues and developments can only be broadcast through correct diligence and there is no correct diligence except by achieving a correct framework, to limit the deviation of ideas and the emergence of groups like ISIS and those who follow their path. "

Published
2021

31. Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis

Author

Zhang, Jing, Zhang, Yingyuan, Wu, Depei, Cao, Guoying, Hamed, Kamal, Desai, Amit, Aram, Jalal A., Guo, Xuan, Fayyad, Rana, Cornely, Oliver A., Zhang, Jing, Zhang, Yingyuan, Wu, Depei, Cao, Guoying, Hamed, Kamal, Desai, Amit, Aram, Jalal A., Guo, Xuan, Fayyad, Rana, and Cornely, Oliver A.

Abstract

Background Isavuconazole is a broad-spectrum triazole for the treatment of invasive fungal disease (IFD). Objective To investigate the clinical experience with isavuconazole in Chinese individuals. Patients/Methods Participants were Chinese healthy volunteers from a Phase I pharmacokinetics (PK) and safety study of single/multiple doses of isavuconazole (n = 36) and Chinese patients from the global Phase III SECURE study that assessed safety and efficacy of isavuconazole vs voriconazole for IFD treatment (n = 26). Results No clinically relevant differences in PK were found between Chinese and Western participants, although exposure was increased in Chinese volunteers. Treatment-emergent adverse events (TEAEs) were reported in 75.0% of healthy volunteers, many of which were infusion-related. No serious AEs were reported. In SECURE, findings in Chinese patients (n = 26) were similar to the global population. For patients who received >= 1 dose of study drug, allcause mortality from first dose to Day 42 was 10.0% (1/10) with isavuconazole and 25.0% (4/16) with voriconazole (treatment difference [95% confidence interval, CI]: -15.0% [-43.2%, 13.2%]). Overall response at the end of treatment for patients with proven/probable IFD was 25.0% and 16.7% with isavuconazole and voriconazole, respectively (treatment difference [95% CI] -8.3% [-60.2%, 43.5%]). Isavuconazole was associated with lower incidence of hepatobiliary, eye, skin, subcutaneous tissue and psychiatric disorders compared with voriconazole and lower incidence of treatment-related TEAEs, serious TEAES or death overall. Conclusions Although further research is required, this study demonstrated a favourable risk-benefit profile of isavuconazole in Chinese patients.

Published
2021

32. Patient Characteristics and Risk Factors in Invasive Mold Infections: Comparison from a Systematic Review and Database Analysis

Author

Sung,Anita H, Martin,Stephan, Phan,Bryant, Benigno,Michael, Stephens,Jennifer, Chambers,Richard, Aram,Jalal A, Sung,Anita H, Martin,Stephan, Phan,Bryant, Benigno,Michael, Stephens,Jennifer, Chambers,Richard, and Aram,Jalal A

Abstract

Anita H Sung,1 Stephan Martin,2 Bryant Phan,1 Michael Benigno,1 Jennifer Stephens,2 Richard Chambers,1 Jalal A Aram1 1Pfizer Inc, New York, NY, USA; 2OPEN Health, Bethesda, MD, USACorrespondence: Anita H SungPfizer, 235 E 42nd St, New York, NY, 10017, USATel +1 212 733-2323Email anita.sung@pfizer.comIntroduction: Diagnosis and treatment of invasive mold infections (IMI) can be challenging and IMI is a significant source of morbidity and mortality. Invasive aspergillosis (IA) and invasive mucormycosis (IM) are two of the most common mold infections. A better understanding of patient comorbidities and risk factors that predispose IMI may help clinicians to refine the difficult diagnostic and treatment process.Methods: A systematic literature review (SLR) was conducted (January 2008–October 2019) for studies reporting comorbidities/risk factors of patients with IA or IM (Phase I), followed by an analysis on the Optum® US EHR database of prominent risk factor cohorts based on SLR findings and expert opinion (Phase II). From the four identified patient cohorts: 1) patients undergoing solid organ transplant (SOT) and patients with 2) hematologic cancers, 3) diabetes, or 4) lung disease, rates of IA, IM, or concurrent IA and IM; patient comorbidities; and Charlson Comorbidity Index (CCI) scores were reported.Results: The SLR included 88 studies, and 46 were used to select comorbidities/risk factors cohorts in IA and IM patients. The most important comorbidities/risk factors in IA and IM patients were diabetes, lung disease, hematological malignances, and SOT. In the Optum database (N=101,340,454 patients), IA rates were highest in lung transplant (10.81%) patients and IM rates were highest in intestine transplant (0.83%) patients, lung transplant (0.43%), and hematopoietic stem cell transplant (0.49%). CCI scores were elevated in all mold infection groups compared to the total Optum cohort.Conclusion: The current study describes patient comorbidity and risk factors asso

Published
2021

33. Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary

Author

Jing, Ran, Morrissey, Ian, Xiao, Meng, Sun, Tian-Shu, Zhang, Ge, Wei, Kang, Guo, Da-Wen, Aram, Jalal A, Wang, Jeffrey, Utt, Eric A, Wang, Yao, and Xu, Ying-Chun

Abstract

What is this summary about?Molds are types of fungus that can cause sickness and death. Mold infections are increasing in China. Until 2022, medicines that can effectively treat all mold infections were still lacking in China. This summary of a study originally published in the journalInfection and Drug Resistance. The study took place in China and tested a medicine called isavuconazole on mold samples to check if isavuconazole can be used to treat mold infections. Isavuconazole became available in China in January 2022 as a capsule (a hard gel-covered pill filled with a dose of medicine) and in June 2022 as an injection or a shot.What were the results?Isavuconazole stopped the growth of most molds. Other medicines were needed at higher amounts to stop the growth of molds.What do the results of the study mean?Isavuconazole is another option to treat mold infections in China.

Published
2023
Full Text
View/download PDF

35. Additional file 1: of Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data

Author

Jin, Jie, Depei Wu, Liu, Yang, Sisi Pan, Yan, Jean, Aram, Jalal, Yin-Jun Lou, Haitao Meng, Xiaochen Chen, Xian’An Zhang, Schwartz, Ilan, and Patterson, Thomas

Abstract

List of ethics committees or institutional review boards of the investigational centers. This file provides a list of the investigational center numbers and their associated Institutional Review Boards or Independent Ethics Committees. (DOCX 48 kb)

Published
2019
Full Text
View/download PDF

36. A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to18 Years of Age

Author

Roilides, Emmanuel, Carlesse, Fabianne, Leister-Tebbe, Heidi, Conte, Umberto, Yan, Jean L, Liu, Ping, Tawadrous, Margaret, Aram, Jalal A, Queiroz-Telles, Flavio, and Gentile, Giuseppe

Subjects
anidulafungin, invasive candidiasis, candidemia, pediatric, Microbiology (medical), Male, medicine.medical_specialty, Antifungal Agents, Internationality, Echinocandin, Adolescent, MEDLINE, Anidulafungin, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Open label study, 030225 pediatrics, Internal medicine, medicine, Humans, Candidiasis, Invasive, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Child, Candida, business.industry, candidemia, Safety tolerability, Invasive candidiasis, invasive candidiasis, bacterial infections and mycoses, medicine.disease, Clinical trial, pediatric, Infectious Diseases, Treatment Outcome, Child, Preschool, Pediatrics, Perinatology and Child Health, Administration, Intravenous, Female, business, medicine.drug
Abstract

Treatment with an echinocandin is recommended as first-line therapy for patients with invasive candidiasis (ICC) including candidemia. Little is known about the efficacy and safety of anidulafungin in children with ICC.Eligible patients with ICC 2 to18 years old were enrolled into this prospective, open-label, noncomparative, international study (NCT00761267) and received anidulafungin for 10-35 days (3 mg/kg on day 1, 1.5 mg/kg daily thereafter). Safety was assessed through week 6 follow-up. Efficacy, measured by global response (based on clinical and microbiologic responses), was assessed at end of intravenous treatment (EOIVT), end of treatment, weeks 2 and 6 follow-up.Forty-nine patients (n = 19, 2 to5 years; n = 30, 5 to18 years) received ≥1 dose of anidulafungin (median 11 days; range 1-35 days) and were assessed for safety. Among 48 patients with a Candida species isolated, C. albicans (37.5%), C. parapsilosis (25.0%), C. tropicalis (14.6%) and C. lusitaniae (10.4%) were the most frequent Candida spp. All patients reported ≥1 treatment-emergent adverse event, with diarrhea (22.4%), vomiting (24.5%) and pyrexia (18.4%) being most frequent. Five patients discontinued treatment because of adverse events, of which 4 discontinuations were considered related to anidulafungin. All-cause mortality was 8.2% (4/49) by EOIVT and 14.3% (7/49) by week 6 follow-up. None of 7 deaths during the study period were considered treatment related. Global response success rate was 70.8% at EOIVT.These data support the use of anidulafungin as a treatment option for ICC in children 2 to18 years old at the studied dose.

Published
2018

39. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

Author

Kullberg, Bart Jan, primary, Vasquez, José, additional, Mootsikapun, Piroon, additional, Nucci, Marcio, additional, Paiva, José-Artur, additional, Garbino, Jorge, additional, Yan, Jean Li, additional, Aram, Jalal, additional, Capparella, Maria Rita, additional, Conte, Umberto, additional, Schlamm, Haran, additional, Swanson, Robert, additional, and Herbrecht, Raoul, additional

Published
2017
Full Text
View/download PDF

42. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials.

Author

Jan Kullberg, Bart, Vasquez, José, Mootsikapun, Piroon, Nucci, Marcio, Paiva, José-Artur, Garbino, Jorge, Li Yan, Jean, Aram, Jalal, Capparella, Maria Rita, Conte, Umberto, Schlamm, Haran, Swanson, Robert, Herbrecht, Raoul, Kullberg, Bart Jan, and Yan, Jean Li

Subjects
TREATMENT effectiveness, BLIND experiment, ANTIFUNGAL agents, CLINICAL trials, CANDIDIASIS, FLUCONAZOLE, INTRAVENOUS therapy, PEPTIDES, INVASIVE candidiasis
Abstract

Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non- albicans Candida species.Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials.gov). In all studies, patients with culture-confirmed invasive candidiasis received a single intravenous (iv) loading dose of anidulafungin 200 mg on day 1, followed by 100 mg once-daily. Switch to oral fluconazole or voriconazole was permitted after 5-10 days of iv treatment in all studies except one. Antifungal treatment (iv plus oral therapy if applicable) was maintained for ≥14 days after the last positive Candida culture. The primary endpoint was successful global response at end of iv therapy (EOivT) in the modified ITT (mITT) population.Results: In total, 539 patients were included (mITT population). The most common baseline Candida species were Candida albicans (47.9%), Candida glabrata (21.0%), Candida tropicalis (13.7%), Candida parapsilosis (13.2%) and Candida krusei (3.5%). Median duration of anidulafungin iv treatment was 10.0 days. The global response success rate at EOivT was 76.4% (95% CI 72.9%-80.0%). All-cause mortality was 13.0% on day 14 and 19.1% on day 28. Adverse events (AEs) were consistent with the known AE profile for anidulafungin.Conclusions: These data demonstrate that anidulafungin is effective for treatment of candidaemia and invasive candidiasis in a broad patient population. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

43. Tissue Distribution of Anidulafungin in Neonatal Rats

Author

Ripp, Sharon L., primary, Aram, Jalal A., additional, Bowman, Christopher J., additional, Chmielewski, Gary, additional, Conte, Umberto, additional, Cross, David M., additional, Gao, Hongying, additional, Lewis, Elise M., additional, Lin, Jian, additional, Liu, Ping, additional, and Schlamm, Haran T., additional

Published
2012
Full Text
View/download PDF

45. Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida aurisUsing an Immunocompromised Murine Model of Disseminated Candidiasis

Author

Gamal, Ahmed, Long, Lisa, Herrada, Janet, Aram, Jalal, McCormick, Thomas S., and Ghannoum, Mahmoud A.

Abstract

Antifungal activity of anidulafungin, voriconazole, isavuconazole, and fluconazole in the treatment of Candida auriswas determined in vitroand in vivo. MICs for anidulafungin, voriconazole, isavuconazole, fluconazole, and amphotericin B were 0.5, 1, >64, 0.25, and 4 μg/ml, respectively.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results